Yifah Yaron

Cabozantinib in Progressive Medullary Thyroid Cancer

Rossella Elisei, Martin Schlumberger, Stefan Müller et al. · Journal of Clinical Oncology · 2013 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +14

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

Martin Schlumberger, Rossella Elisei, Stefan Müller et al. · Annals of Oncology · 2017 · 239 citations · Full text

Medicine, Oncology, Pharmacology +6

Tiggrin, a novel <i>Drosophila</i> extracellular matrix protein that functions as a ligand for <i>Drosophila</i> αPS2βPS integrins

Frances J. Fogerty, Liselotte I. Fessler, Thomas A. Bunch et al. · Development · 1994 · 171 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.

Patrick Schöffski, Rossella Elisei, Stefan Müller et al. · Journal of Clinical Oncology · 2012 · 92 citations

Medicine, Oncology, Pharmacology +13

Characterization of HOX Gene Expression During Myelopoiesis: Role of HOX A5 in Lineage Commitment and Maturation

John F. Fuller, Jeanne K. McAdara, Yifah Yaron et al. · Blood · 1999 · 88 citations

Life Sciences, Biology, Developmental Biology +16